Valuation: DCF-based valuation of £195m We value GW at £195m, or £1.46 per share, based on a DCF analysis. Sativex in MS spasticity contributes 53p per share, with cash adding another 13p. Thus, the current share price of 58p appears to discount any new Sativex indications, pipeline success, or potential licensing deals, which in our view represents a clear buying opportunity.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.